Frequency and determinant factors for calcification in neurocysticercosis

Arroyo Hurtado, Gianfranco; Pretell, E. Javier; Gonzales, Isidro; Nash, Theodore E.; Del Brutto, Oscar H.; O'Neal, Seth E.; García Lescano, Héctor Hugo; Gilman, Robert Hugh; Bustos Palomino, Javier Arturo; Cysticercosis Working Group in Peru; Soto Becerra, Percy; Saavedra Pastor, Herbert; Gonzalez Zariquiey, Armando Emiliano

dc.contributor.author	Bustos Palomino, Javier Arturo
dc.contributor.author	Arroyo Hurtado, Gianfranco
dc.contributor.author	Gilman, Robert Hugh
dc.contributor.author	Soto Becerra, Percy
dc.contributor.author	Gonzales, Isidro
dc.contributor.author	Saavedra Pastor, Herbert
dc.contributor.author	Pretell, E. Javier
dc.contributor.author	Nash, Theodore E.
dc.contributor.author	O'Neal, Seth E.
dc.contributor.author	Del Brutto, Oscar H.
dc.contributor.author	Gonzalez Zariquiey, Armando Emiliano
dc.contributor.author	García Lescano, Héctor Hugo
dc.contributor.author	Cysticercosis Working Group in Peru
dc.date.accessioned	2020-07-14T00:00:59Z
dc.date.available	2020-07-14T00:00:59Z
dc.date.issued	2021
dc.identifier.uri	https://hdl.handle.net/20.500.12866/8245
dc.description.abstract	BACKGROUND: Neurocysticercosis is a major cause of acquired epilepsy. Larval cysts in the human brain eventually resolve and either disappear or leave a calcification that is associated with seizures. In this study, we assessed the proportion of calcification in parenchymal neurocysticercosis and risk factors associated with calcification. METHODS: Data for 220 patients with parenchymal NCC from 3 trials of antiparasitic treatment were assessed to determine what proportion of the cysts that resolved 6 months after treatment ended up in a residual calcification at 1 year. Also, we evaluated the risk factors associated with calcification. RESULTS: The overall proportion of calcification was 38% (188/497 cysts, from 147 patients). Predictors for calcification at the cyst level were cysts larger than 14 mm (risk ratio [RR], 1.34; 95% confidence interval [CI], 1.02-1.75) and cysts with edema at baseline (RR, 1.39; 95% CI, 1.05-1.85). At the patient level, having had more than 24 months with seizures (RR, 1.25; 95% CI, 1.08-1.46), mild antibody response (RR, 1.14; 95% CI, 1.002-1.27), increased dose albendazole regime (RR, 1.26; 95% CI, 1.14-1.39), lower doses of dexamethasone (RR, 1.36; 95% CI, 1.02-1.81), not receiving early antiparasitic retreatment (RR, 1.45; 95% CI, 1.08-1.93), or complete cure (RR, 1.48; 95% CI, 1.29-1.71) were associated with a increased risk of calcification. CONCLUSIONS: Approximately 38% of parenchymal cysts calcify after antiparasitic treatment. Some factors associated with calcification are modifiable and may be considered to decrease or avoid calcification, potentially decreasing the risk for seizure relapses	en_US
dc.language.iso	eng
dc.publisher	Oxford University Press
dc.relation.ispartofseries	Clinical Infectious Diseases
dc.rights	info:eu-repo/semantics/restrictedAccess
dc.rights.uri	https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject	Perú	en_US
dc.subject	Cysticercosis	en_US
dc.subject	Taenia solium	en_US
dc.subject	calcification	en_US
dc.subject	risk factors	en_US
dc.title	Frequency and determinant factors for calcification in neurocysticercosis	en_US
dc.type	info:eu-repo/semantics/article
dc.identifier.doi	https://doi.org/10.1093/cid/ciaa784
dc.subject.ocde	https://purl.org/pe-repo/ocde/ford#3.03.08
dc.relation.issn	1537-6591